PM&R
Volume 1, Issue 1 , Pages 5-13 , January 2009

Practice Parameter: The Evaluation of Distal Symmetric Polyneuropathy: The Role ofLaboratory and Genetic Testing (An Evidence-Based Review) Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation

  • J.D. England, MD

      Affiliations

    • Louisiana State University Health Sciences Center, New Orleans; holds financial interests in Pfizer
    • ,
  • G.S. Gronseth, MD

      Affiliations

    • University of Kansas, Kansas City; holds financial interests in Pfizer and GlaxoSmithKline and Boeheringer Ingelheim for speaker honoraria and Ortho-McNeil for serving on the IDMC Committee
    • ,
  • G. Franklin, MD

      Affiliations

    • University of Washington, Seattle; has nothing to disclose
    • ,
  • G.T. Carter, MD

      Affiliations

    • Providence Health System, Southwest Washington; has nothing to disclose
    • ,
  • L.J. Kinsella, MD

      Affiliations

    • St. Louis University School of Medicine, St. Louis, MO; has received royalties from the American Medical Resources, Enduring Medical Materials (CD/DVD), has received honorarium from Medical Education Resources, CME LLC, Expert Witness testimony and record review, Peters Marketing Research, Delve Marketing Research, Cross Country Education and American Medical Seminars. Dr. Kinsella holds corporate appointments with Cross Country Education and Forest Park Hospital
    • ,
  • J.A. Cohen, MD

      Affiliations

    • Dartmouth Hitchcock Medical Center, Lebanon, NH; has nothing to disclose
    • ,
  • A.K. Asbury, MD

      Affiliations

    • University of Pennsylvania School of Medicine, Philadelphia; receives residual royalties from Elsevier for editorial work done prior to 2005. He receives honoraria from Dana Foundation, NY and the International Society for Neuroimmunology. His wife is a consultant for the Dana Foundation
    • ,
  • K. Szigeti, MD, PhD

      Affiliations

    • Baylor College of Medicine, Houston, TX; has nothing to disclose
    • ,
  • J.R. Lupski, MD, PhD

      Affiliations

    • Baylor College of Medicine, Houston, TX; holds financial interests in Athena Diagnostics and has received research funding from NIH/NEI, NIH/NIDCR, Charcot-Marie-Tooth Association and the March of Dimes
    • ,
  • N. Latov, MD

      Affiliations

    • Weill Medical College of Cornell, New York, NY; serves on as a Scientific Advisor for Quest Diagnostics and is a member of a Steering Committee, Talecris Biotherapeutics. Dr. Latov receives royalties from Demos publications and has received research support from the NIH and Talecris Biotherapeutics. He holds stock options in Therapath LLC and is the beneficiary of license fee payments from Athena Diagnostics to Columbia University. He has given expert testimony in legal proceedings related to neuropathy and has prepared an affidavit with regarding to the legal proceeding related to neuropathy
    • ,
  • R.A. Lewis, MD

      Affiliations

    • Wayne State University School of Medicine, Detroit, MI; holds financial interests in Talecris and has received research funding from MDA and CMTA. He estimates that approximately 33% of his clinical effort is spent on electromyography. He has received payment for expert testimony regarding the use of IVIg in CIDP; neuropathic pain after breast reduction
    • ,
  • P.A. Low, MD

      Affiliations

    • Mayo Clinic, Rochester, MN; has served as a consultant for WR Medical, Viatris, Eli Lilly and Company, Chelsea Therapeutics and Quigley Corporation
    • ,
  • M.A. Fisher, MD

      Affiliations

    • Loyola University Chicago Stritch School of Medicine and the Hines VAH, IL; has nothing to disclose
    • ,
  • D.N. Herrmann

      Affiliations

    • University of Rochester Medical Center, NY; estimates that approximately 15-20% of his clinical effort is spent on skin biopsies
    • ,
  • J.F. Howard, MD

      Affiliations

    • University of North Carolina, Chapel Hill; serves on a myasthenia gravis medical scientific board, has served as an Associate Editor, Journal of Clinical Neuromuscular Disease (1998-2006), receives honoraria from Duke University Medical Center, and Medical Educational Resources. He is the director of MEG laboratories and estimates that 75% of his time is spent there. He also holds stock options in GE, Pfizer and Johnson & Johnson. In addition, he has provided an affidavit on two cases regarding myasthenia gravis
    • ,
  • G. Lauria

      Affiliations

    • Fondazione IRCCS National Neurological Institute “Carlo Besta”, Milan, Italy; holds financial interests in GlaxoSmithKline, Formenti-Grunenthal, Mitsubishi Pharma, and Agave. In addition he has received research funding from Pfitzer, Formenti-Grunenthal, Agave, Italian Ministry of Health and Regione Lombardia
    • ,
  • R.G. Miller, MD

      Affiliations

    • California Pacific Medical Center, San Francisco; holds financial interests in Celgene and Pathologica
    • ,
  • M. Polydefkis

      Affiliations

    • John Hopkins Medical Institutions, Baltimore, MD; holds financial interests in DSMB, Pfizer, Johnson & Johnson, Mitsubishi Pharma, Merck, Xenoport and GSK. He has received research funding from JDRF, NIH, Astellas Pharma, Mitsubishi Pharma and Sanofi-Aventis. He estimates that 10% of his clinical effort is devoted to EMG, 5% to skin biopsy and <1% on lumbar puncture
    • ,
  • A.J. Sumner, MD

      Affiliations

    • Louisiana State University Health Sciences Center, New Orleans; has received payment for expert testimony in the possible neurotoxic injury of the peripheral nerve
    • Corresponding Author InformationSend correspondence to: American Academy of Physical Medicine and Rehabilitation

References 

  1. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research (Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation). Neurology. 2005;64:199–207
  2. Martyn CN, Hughes RAC. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310–318
  3. England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363:2151–2161
  4. Barohn RJ. Approach to peripheral neuropathy and myopathy. Seminars Neurology. 1998;18:7–18(Class III)
  5. Jann S, Beretta S, Bramerio M, Defanti CA. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle Nerve. 2001;24:1197–1201(Class III)
  6. Lubec D, Muellbacher W, Finsterer J, Mamoli B. Diagnostic work-up in peripheral neuropathy: An analysis of 171 cases. Postgrad Med J. 1999;75:723–727(Class III)
  7. Wolfe GI, Baker NS, Amato AA, et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol. 1999;56:540–547(Class III)
  8. Notermans NC, Wokke JH, Franssen H, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993;10:1066–1071(Class III)
  9. Notermans NC, Wokke JH, van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry. 1994;57:1525–1527(Class III)
  10. Fagius J. Chronic cryptogenic polyneuropathy. Acta Neurol Scand. 1983;67:173–180(Class III)
  11. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981;10:222–226(Class IV)
  12. McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC. Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry. 1984;47:530–535(Class III)
  13. Johannsen L, Smith T, Havsager A-M, et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neuromusc Dis. 2001;3:47–52(Class III)
  14. Saperstein DS, Wolfe GI, Gronseth GS, et al. Challenges in the identification of cobalamin-deficient polyneuropathy. Arch Neurol. 2003;60:1296–1301(Class III)
  15. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2–11(Class II)
  16. Lindenbaum J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency (II. Relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations). Am J Hematol. 1990;34:99–107(Class II)
  17. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96:239–246(Class III)
  18. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–1231(Class III)
  19. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24:1225–1228(Class IV)
  20. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polyfefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–111(Class III)
  21. Hughes RA, Umapathi T, Gray IA, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127:1723–1730(Class III)
  22. Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. Prevalence of monoclonal proteins in peripheral neuropathy. Neurology. 1981;31:1480–1483(Class III)
  23. Kahn SN, Bina M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem. 1988;34:1633–1635
  24. Boerkoel CF, Takashima H, Garcia CA, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol. 2002;51:190–201(Class I)
  25. Boerkoel CF, Takashima H, Lupski JR. The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy. Curr Neurol Neurosci Rep. 2002;2:70–77
  26. Hoogendijk JE, Hensels GW, Gabreels-Festen AA, et al. De-novo mutation in hereditary motor and sensory neuropathy type I. Lancet. 1992;339:1081–1082(Class II)
  27. Wise CA, Garcia CA, Davis SN, et al. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet. 1993;53:853–863(Class II)
  28. Bort S, Nelis E, Timmerman V, et al. Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. Hum Genet. 1997;99:746–754(Class I)
  29. Janssen EA, Kemp S, Hensels GW, et al. Connexin32 gene mutations in X-linked dominant Charcot-Marie-Tooth disease (CMTX1). Hum Genet. 1997;99:501–505(Class I)
  30. Silander K, Meretoja P, Juvonen V, et al. Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth disease and related neuropathies. Hum Mutat. 1998;12:59–68(Class II)
  31. Leonardis L, Zidar J, Ekici A, Peterlin B, Rautenstrauss B. Autosomal dominant Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies: detection of the recombination in Slovene patients and exclusion of the potentially recessive Thr118MetPMP22 point mutation. Int J Mol Med. 1998;1:495–501(Class III)
  32. Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996;4:25–33(Class I)
  33. Nicholson GA. Mutation testing in Charcot-Marie-Tooth neuropathy. Ann NY Acad Sci. 1999;883:383–388(Class II)
  34. Mersiyanova IV, Ismailov SM, Polyakov AV, et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat. 2000;15:340–347(Class II)
  35. Mostacciuolo ML, Righetti E, Zortea M, et al. Charcot-Marie-Tooth disease type 1 and related demyelinating neuropathies: Mutation analysis in a large cohort of Italian families. Hum Mutat. 2001;18:32–41(Class I)
  36. Choi BO, Lee MS, Shin SH, et al. Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. Hum Mutat. 2004;24:185–186(Class I)
  37. Verhoeven K, Claeys KG, Zuchner S, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain. 2006;129:2093–2102(Class II)

 Published simultaneously in Neurology and Muscle & Nerve. Approved by the AAPM&R Board of Governors April 7, 2008; by the AANEM Board of Directors May 1, 2008; and the AAN Board of Governors August 20, 2008.

 Author affiliations and disclosures are provided at the end of the article. Supplemental data available at www.pmrjournal.org

 With regards to conflicts of interest, the authors disclose the following:

PII: S1934-1482(08)00038-5

doi: 10.1016/j.pmrj.2008.11.010

PM&R
Volume 1, Issue 1 , Pages 5-13 , January 2009

Article Tools

* Image Usage & Resolution